drug discovery

Curia is a global contract research, development and manufacturing organization (CDMO) with over 30 years of experience guiding clients through drug discovery, development, and manufacturing. It offers services across Small Molecule, Generic APIs, Sterile Drug Product, and Biologics, operating an integrated network of 20+ facilities and 3,000+ professionals across North America, Europe, and India.

analytical testingantibody discovery and engineeringchemical process R&Ddownstream process developmentfermentationflow chemistryGMP manufacturinghigh potency API (HPAPI) manufacturingLNP formulationmammalian cell line developmentmRNA process developmentrecombinant antibody productionrecombinant protein productionsterile API manufacturingupstream process development

Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology. It discovers, develops, and commercializes potential medicines for diseases of impaired muscle function, including heart failure, hypertrophic cardiomyopathy (HCM), and neuromuscular diseases such as ALS. Its research focuses on modulating proteins in the sarcomere, including myosin and troponin, and it has a pipeline of small molecule muscle activators and inhibitors.

clinical trialscommercialization of medicinesdrug developmentmuscle biology research

Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company focused on discovering, developing and delivering breakthrough medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS and an international site in Zug, Switzerland, Deciphera is a member of Ono Pharma and leads Ono's expansion in the U.S. and Europe. The company develops medicines across oncology, immunology & inflammation, and neurology.

AI-enabled drug discoveryclinical developmentcommercial-stage manufacturing and distributionData Analyticskinase-inhibitor science

Degromics Bio, Inc. is a company whose mission is to apply an innovative approach to help patients with well-defined cancer drivers by targeting the entire protein, aiming to overcome past failures with a new approach.

medicinal chemistrytranslational cancer biology

Diamond Therapeutics is a psychedelic pharmaceutical company developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines. Its first clinical program focuses on accessible psilocybin-based drugs intended to deliver rapid therapeutic outcomes without perceptual side effects. It is also advancing a pipeline of tryptamine analogs and small organic molecules that modulate selective serotonin receptors and neurotrophic receptor signalling.

clinical trialsformulation developmentpre-clinical and clinical neuropsychiatric drug development

Dolinnov is a biotech company developing Precision Pump Modulators (PPMs), a novel class of non-opioid medicines for chronic pain. It is the first company worldwide to develop a lipid antisense oligonucleotide (L-ASO) therapy targeting FXYD2, a regulator of neuronal excitability in the DRG, to treat neuropathic and inflammatory chronic pain, including pain associated with rare diseases.

antisense oligonucleotide therapy developmentpreclinical research

Dynamiko Pharmaceutics, LLC is dedicated to providing and developing anti-cancer therapies that are selective and potentially more effective therapeutics. Its mission is to offer lifesaving therapeutic alternatives to cancer patients that improve survivorship outcome and quality of life, focusing on the discovery and development of selective and targeted drugs. Its innovation stems from identifying nature-derived compounds that show selectivity against cancer cells and are safe for healthy tissue.

drug developmentnatural product screeningsynthesis and modification of natural products

EicOsis Human Health is a clinical-stage pharmaceutical company developing oral medicines targeting soluble epoxide hydrolase (sEH) to treat pain, inflammation, and neuroinflammatory and neurological disorders. Its lead drug candidate, EC5026, is a first-in-class oral sEH inhibitor being studied as a non-opioid treatment for neuropathic pain, Parkinson's disease, Alzheimer's disease, and other conditions.

clinical trialssEH inhibitiontranslational science

Eisai Inc. is the U.S. company of Eisai Co., Ltd., a pharmaceutical company guided by its human health care (hhc) mission, placing patients and their families first. With almost 40 years of research, development and manufacturing in the U.S., Eisai focuses on drug discovery for challenging neurological conditions such as Alzheimer's disease, sleep disorders and narcolepsy, and on oncology toward a cancer-free future.

clinical trialsmanufacturingresearch and development

ENCUE is a Northwestern spinout developing novel modulators and therapeutics for neurodegenerative and psychiatric disorders. Its approach targets synaptic function and neuroplasticity to restore synaptic health and normal cognition, with a focus on the IGF2R receptor. The company reports six molecules currently in Phase 2/3 clinical trials.

clinical research and developmentmedicinal chemistrytherapeutic development

Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder. Founded through CU Boulder's Embark Deep Tech Startup Creator, the company targets PEG10, a newly discovered driver of ALS and neurodevelopmental disorders, with two patented therapeutic programs aimed at neutralizing PEG10.

molecular biology researchtherapeutic development

Endobios Biotech is an EU-based startup advancing a potential first-in-class small molecule anticonvulsant, currently in the early preclinical stages of drug development. Its lead candidate ENB-002 is a new chemical scaffold (molecular weight <300 g/mol) based on unpublished fungal-derived compounds, with in vivo anticonvulsant activity in a mouse model, preliminary blood-brain barrier permeability data, and secondary capacity against neuropathic pain.

preclinical drug developmentsmall molecule development

Envision Research Inc is a clinical research organization whose mission is to advance medical research through innovative solutions and improve healthcare outcomes by developing groundbreaking therapies and technologies. Its team consists of experienced principal investigators and dedicated staff delivering patient-focused research across multiple therapeutic areas, partnering with sponsors and CROs to deliver efficient clinical trials.

clinical researchclinical trial recruitment and enrollmentmedical device developmentparticipant retentionregulatory and GCP compliance

Epigenetix Inc. designs epigenetic drugs; its first drug, EP31670 (NEO2734), is a first-in-class oral once daily dual BRD4 and p300/CBP inhibitor in clinical trials (late stage 1) focused on myelofibrosis and other cancers. Clinical trials are ongoing at the University of Miami (Sylvester), MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, and the University of Washington/Fred Hutchinson Cancer Research Center.

clinical developmentepigenetic drug design

Epoulosis Therapeutics is a biotech company focused on the development and commercialization of novel therapeutics to treat diabetic complications such as diabetic foot ulcers and diabetic neuropathy. Its pipeline includes EPO-01, and it seeks strategic collaborations including in-licensing and co-development partnerships.

commercialization of novel therapeuticsdrug development

Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class liver- and kidney-specific acetyl-CoA metabolic enzyme inhibitors. Its lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden. The company is led by a team with deep exper

drug developmentin vivo and translational studiespreclinical studies

Etiome is a biotechnology company developing and deploying Biostaged Medicines, stage-specific therapies delivered to the right patient population at the right time. By building detailed models of molecular changes over the course of disease and applying single-cell omics and artificial intelligence, Etiome uncovers hidden patterns of disease progression to identify disease-modifying targets and biomarkers. Founded in 2021, originating from Flagship Pioneering's Preemptive Health and Medicine initiative.

Artificial Intelligencebiomarker discoverycomputational biologymachine learningsingle-cell omicstarget discovery

FAKnostics is a biopharmaceutical company developing therapeutics and diagnostics based on its Focal Adhesion Kinase (FAK) platform technology to combat metastatic cancers and fibrosis. Its proprietary hydrocarbon-stapled peptide FN-2012 blocks the FAK FAT domain, and its FAKnosTEST companion diagnostic detects cancer in early stages. The company reports more than 30 years of FAK research leadership and has 3 pre-clinical programs in fibrotic diseases.

computational drug discoveryimmunohistochemical (IHC) diagnosticsin-vitro approachesin vivo studiespharmacologystructure-based drug design

Fimbrion Therapeutics, Inc. is a St. Louis-based company whose mission is to discover, develop, and commercialize antimicrobial-sparing and -enabling drugs for the prevention and treatment of infectious diseases caused by bacteria, including drug-resistant strains. Its initial focus is an orally active drug to prevent and treat urinary tract infections (UTIs), targeting bacterial adhesins rather than bacterial viability.

commercializationdrug development

FLAG Therapeutics, Inc. is a near-term clinical stage company headquartered in Raleigh, North Carolina, focused on developing new small molecule therapeutics for difficult-to-treat cancers. Its lead candidate, FLAG-003, targets diffuse intrinsic pontine glioma (DIPG) and glioblastoma multiforme (GBM) and is projected to enter Phase 1/2 clinical development in early 2026 in children with DIPG. The company leverages three proprietary drug discovery platforms and holds an exclusive worldwide licensing agreement with Duquesne University.

computer modeling/artificial intelligence in drug discoverydrug developmentsmall-molecule therapeutics

Flavocure Biotech, Inc. is a biotechnology company focused on discovering and developing next-generation cures for patients, aiming to transform natural products into new cures. It is developing a Theranostic platform called NanoCaflanone™ targeting neurological diseases such as Alzheimer's and Parkinson's disease, as well as aggressive and rare cancers including pancreatic cancer and brain cancer.

drug delivery across blood-brain barrierMRI imagingnanoparticle-based theranostic platformtherapeutic development

Frontage Laboratories, Inc. is a global pharmaceutical development organization (PDO) and CRO providing integrated, science-driven product development services throughout the drug discovery and development process. It assists clients in advancing molecules through development to commercial launch, enabling innovators, generic, and consumer health companies to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets.

analytical servicesbioanalysisbiostatisticscentral lab servicesclinical trial material manufacturingcommercial manufacturingDART servicesdata managementDMPKdrug developmentformulation developmentgenetic toxicologyGMP routine testingmass spectrometrymethod development and validationsafety pharmacologystability programsstatistical programmingtoxicology

Functional Longevity Labs (FLL) is a Maryland-based early-stage pharmaceutical company founded in 2024 that develops therapeutics targeting the root biologic mechanisms of aging to maximize healthspan and delay age-associated disease. It operates under a CRADA with the National Institute on Aging at NIH and is developing FLL-001, a first-in-class YARS1 Chronomodulator for Alzheimer's disease.

biomarker-driven developmentgeroscience researchpreclinical development

Gamma Biotherapeutics is a private, clinical-stage biotechnology company discovering and developing therapeutics that help the immune system fight cancer. Its lead program M3T01, a FasL-neutralizing monoclonal antibody, is advancing through a Phase 1 first-in-human clinical trial in patients with advanced solid tumors at Providence Cancer Institute in Portland, Oregon.

clinical developmentclinical trialsmonoclonal antibody development